Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Lorazepam

Criteria

Inclusion Criteria:

• Signed informed consent before any study-related procedures start.

• The patient is previously diagnosed with Generalized Anxiety Disorder.

• The patient has a HADS-A (anxiety) score ≥10 at both screening and randomization.

Exclusion Criteria:

• Patient has a lifetime history of schizophrenia or other psychotic disorders

• Patient has a history of seizures or seizure disorder.

• Patient is pregnant or breast feeding.

• Patient has received electroconvulsive treatment (ECT) in the past.